Annovis Bio's buntanetap demonstrated significant improvements in cognitive function for early Parkinson's disease patients with mild dementia in a Phase III clinical trial, preventing cognitive decline compared to placebo.
IRLAB Therapeutics achieved significant advancement in its Parkinson's disease pipeline, with positive Phase I data for IRL757 and receipt of a $2.5 million milestone payment in Q4 2024.
Clinical research in Parkinson's disease (PD) is increasingly focused on disease-modifying therapies (DMTs) to address unmet needs beyond motor symptom management.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.